05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases, infectious diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy; diagnostic preparations; diagnostic reagents. (1) Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services.
2.
METHOD FOR PREDICTING THE OFF-TARGET BINDING OF A PEPTIDE WHICH BINDS TO A TARGET PEPTIDE PRESENTED BY A MAJOR HISTOCOMPATIBILITY COMPLEX
The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to multi-domain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2), wherein VC1 and VC2 dimerise to form the pMHC binding domain; ii) an immune cell engaging domain comprising an antibody light chain variable domain (TCE-VL) linked to an antibody heavy chain variable domain (TCE-VH); and iii) a half-life extending domain comprising a first portion of an IgG Fc region (FC1) and a second portion of an IgG1 Fc region (FC2); wherein the multi-domain binding molecule comprises: a first polypeptide chain in which the immune cell engaging domain is linked to the N terminus of VC1; a second polypeptide chain in which VC2 is linked via its C terminus to the N terminus of FC1; and a third polypeptide chain comprising FC2; and wherein the pMHC binding domain and the immune cell engaging domain are capable of binding to a pMHC complex and a T cell respectively. The binding molecules can be used to treat diseases such as cancer, autoimmune diseases and infectious diseases.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
6.
TCR-ANTI-CD3 ANTIBODY FUSION MOLECULE FOR THE TREATMENT OF HIV INFECTION
The present invention relates to treating human immunodeficiency virus (HIV) infection in a subject. The subject may be administered a composition comprising a heterodimeric TCR-anti-CD3 antibody fusion molecule in a maintenance dose comprising at least 40 µg of the TCR-anti-CD3 antibody fusion molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases, infectious diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy; diagnostic preparations for medical purposes; diagnostic reagents for medical use Scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer, infectious diseases and autoimmune diseases; pharmaceutical research and development services; pharmaceutical testing; conducting pharmaceutical and clinical trials for others; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases, infectious diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy; diagnostic preparations for medical purposes; diagnostic reagents for medical use Scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer, infectious diseases and autoimmune diseases; pharmaceutical research and development services; pharmaceutical testing; conducting pharmaceutical and clinical trials for others; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases, infectious diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy; diagnostic preparations; diagnostic reagents. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases, infectious diseases and autoimmune diseases; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy; diagnostic preparations; diagnostic reagents. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services.
11.
METHODS OF TREATING MELANOMA USING TEBENTAFUSP AND IMMUNE CHECKPOINT INHIBITORS
The present invention relates to the treatment of melanoma in a patient, where the method includes administering to a patient who has or is suspected of having melanoma a therapeutically effective amount of tebentafusp; and a therapeutically effective amount of an immune checkpoint inhibitor. In particular, patients may have metastatic melanoma that is refractory to treatment with an anti-PD(L)1 inhibitor in the metastatic setting or where the patient's melanoma is relapsed following treatment with an anti-PD(L)1 inhibitor.
The invention relates to screening methods. In particular, it relates to a method of identifying a functional TCR from a library of particles, which displays a plurality of different T cell receptors (TCRs). The method may comprise a) exposing the library of particles to a target antigen to identify TCRs that bind to the target antigen, b) transfecting a plurality of T cells with nucleic acid encoding TCRs identified in step (a), c) exposing the plurality of transfected cells to the target antigen, and d) selecting cells having TCR activity in the presence of the target antigen. Transfection of the T cells is such that each T cell comprises a nucleic acid encoding a single TCR from the library of particles, the nucleic acid is integrated into the genome of the T cell at a single identical pre-defined locus, and the TCR is in a single chain format and comprises an alpha chain variable domain, a beta cain variable domain and a constant domain. The T cells do not express endogenous TCR. A T-cell comprising a recombinase mediated landing pad, wherein the T cell constitutively expresses TCR constant domain and does not express endogenous TCR, is also claimed.
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a PRAME positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 5-40 μg; (b) at least one second dose in the range of from 15-80 μg; and then (c) at least one third dose in the range of from 60-400 μg, wherein the second dose is higher than the first dose and the third dose is higher than the second dose, and wherein doses are administered every 6-8 days.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure provides a method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an immunotherapeutic, wherein the subject has been determined to have a T cell signature (TCS) comprising: (a) a composite expression level A comprising the expression of three or more genes selected from Thymocyte Expressed, Positive Selection Associated 1 (TESPA1), Cluster of Differentiation 28 (CD28), G Protein-Coupled Receptor 183 (GPR183), and Zeta-Chain-Associated Protein Kinase 70 (ZAP70) as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2; or (b) a composite expression level B comprising (i) the expression of three or more genes selected from TESPA1, CD28, GPR183 and ZAP70 as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2, minus (ii) the expression of Interferon Alpha Inducible Protein 27 (IFI27) gene as measured by log2tpm, wherein the composite expression level B corresponds to a value of greater than or equal to -0.25.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
16.
HALF-LIFE EXTENDED IMMTAC BINDING CD3 AND A HLA-A*02 RESTRICTED PEPTIDE
The present invention relates to soluble multi-domain binding molecules comprising T cell receptors (TCR) having specificity for an antigen, an immunoglobulin Fc domain or an albumin-binding moiety; and an immune effector domain. Such multi-domain binding molecules are advantageous because they display improved half-life while retaining function.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides a method of treating non-small or small cell lung cancer, or ovarian carcinoma, in a subject, comprising administering to the subject a composition comprising (I) a heterodimeric TCR-anti-CD3 antibody fusion molecule, and (II) a second composition comprising a second active agent, for example wherein the second active agent is a chemotherapeutic agent (e.g., gemcitabine, decitabine, PEGylated liposomal doxorubicin (PLD), or nab-paclitaxel ) or a targeted therapy (e.g., bevacizumab) or a multi-modal therapy (e.g. a chemotherapeutic agent and a targeted therapy), in a dosing regimen, wherein the dosing regimen comprises administering: (i) a first dose comprising 2 to 30 ug of the TCR-anti-CD3 antibody fusion molecule, (ii) a second dose comprising 5 to 60 μg of the TCR-anti-CD3 antibody fusion molecule, and (iii) a maintenance dose comprising 15 to 200 μg of the TCR-anti-CD3 antibody fusion molecule, wherein the maintenance dose is administered in at least three phases, wherein the first phase is administered once every 6 to 8 days, the second phase is administered once every 12 to 16 days, and the third phase is administered once every 26 to 30 days, wherein the second active agent is administered at least once prior to, concurrent with, and/or after the first dose comprising the TCR-anti-CD3 antibody fusion molecule.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to specific binding molecules which bind to the HLA-E restricted peptide RLPAKAPLL (SEQ ID NO: 1) derived from Mycobacterium tuberculosis enoyl-ACP reductase. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 31/06 - Antibacterial agents for tuberculosis
The present invention relates to multi-domain, single-chain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain which binds to a SLLQHLIGL (SEQ ID NO: 1) HLA-A*02 complex, the pMHC domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2); ii) a T cell engaging immune effector domain comprising an antibody light chain variable region (TCE-VL) and an antibody heavy chain variable region (TCE-VH); and iii) a half-life extending domain comprising a first IgG Fc region (FC1) and a second IgG Fc region (FC2), wherein the FC1 region and FC2 region dimerise to form an Fc domain. The binding molecules can be used to treat diseases such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides bispecific molecules comprising a soluble TCR and an immune cell engaging domain, half-life extended bispecific molecules comprising such bispecific molecules and a half-life extending domain, methods of producing such bispecific molecules and half-life extended bispecific molecules, and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides bispecific molecules comprising a soluble TCR and an immune cell engaging domain, half-life extended bispecific molecules comprising such bispecific molecules and a half-life extending domain, methods of producing such bispecific molecules and half-life extended bispecific molecules, and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of viral infections; biological preparations for the treatment of viral infections; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of viral infections; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use
The present disclosure provides a method for purifying a T cell engaging peptide-major histocompatibility complex binding domain (TCE-pMHC) molecule produced by a host cell, the method comprising: isolating a supernatant of a host cell culture comprising the TCE-pMHC molecule to form Product (a), subjecting Product (a) to affinity chromatography wherein the TCE-pMHC molecule is eluted from the affinity chromatography at a pH of about 3.0 to about 4.0 to form Product (b); neutralizing Product (b) by adding MES buffer with a pH of less than 7.0 to form Product (c), wherein Product (c) has a pH of about 5.0 to about 7.0; and subjecting Product (c) to anion exchange chromatography to form Product (d), wherein the pMHC binding domain and the T cell engaging immune effector domain are capable of binding to a pMHC complex and a T cell respectively.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates generally to binding molecules comprising T cell receptor (TCR) mimics that specifically bind to a disease associated peptide-human leukocyte antigen complex (DA-pHLA), compositions comprising such binding molecules, methods of producing such binding molecules, and uses thereof. The TCR mimic may comprise an antibody or an antigen-binding fragment thereof, and may (i) bind to the DA-pHLA with a crossing angle in the range of 150-250 degrees; (ii) with 4 or more peptide residue binding contacts; and (iii) with an affinity of 20 nM or stronger.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure provides a method of treating cutaneous melanoma in a subject comprising administering to the subject a composition comprising a heterodimeric TCR-anti- CD3 antibody fusion molecule in a dosing regimen, wherein the dosing regimen comprises administering: (i) a first dose comprising 2 to 30 ug of the TCR-anti-CD3 antibody fusion molecule, (ii) a second dose comprising 5 to 60 µg of the TCR-anti-CD3 antibody fusion molecule, and (iii) a maintenance dose comprising 15 to 200 µg of the TCR-anti-CD3 antibody fusion molecule, wherein the maintenance dose is administered in at least three phases, wherein the first phase is administered once every 6 to 8 days, the second phase is administered once every 12 to 16 days, and the third phase is administered once every 26 to 30 days, wherein the method is a first line treatment.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of tumorous diseases;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of cancer;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of melanoma, lung
cancer, ovarian cancer, uterine cancer, breast cancer,
urothelial cancer, endometrial cancer, oesophageal cancer,
sarcoma, haematological cancers, acute myeloid leukemia,
chronic myeloid leukemia, hodgkin's lymphoma, and head and
neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of tumorous diseases;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of cancer;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of melanoma, lung
cancer, ovarian cancer, uterine cancer, breast cancer,
urothelial cancer, endometrial cancer, oesophageal cancer,
sarcoma, haematological cancers, acute myeloid leukemia,
chronic myeloid leukemia, hodgkin's lymphoma, and head and
neck cancers.
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
37.
TCR WITH HIGH AFFINITY AND SPECIFICITY SPECIFIC FOR PREPROINSULIN PEPTIDE ALWGPDPAAA BOUND TO HLA-A2*02
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
38.
TCR WITH HIGH AFFINITY AND SPECIFICITY SPECIFIC FOR PREPROINSULIN PEPTIDE ALWGPDPAAA BOUND TO HLA-A2*02
The present invention relates to binding molecules comprising a peptide-major histocompatibility complex (pMHC)-binding domain which binds to a ALWGPDPAAA (SEQ ID NO: 1) peptide (derived from human pre-pro insulin (PPI) protein) presented as a peptide-HLA-A*02 complex. Said binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The binding molecules of the invention have high affinity and high specificity for the ALWGPDPAAA (SEQ ID NO: 1)-HLA-A*02 complex. The binding molecules may further comprise an immune suppressor and/or a half-life extending domain. Such binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as diabetes.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
METHOD FOR PREDICTING THE OFF-TARGET BINDING OF A PEPTIDE WHICH BINDS TO A TARGET PEPTIDE PRESENTED BY A MAJOR HISTOCOMPATIBILITY COMPLEX
The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a MAGE-A4 positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 10-20 μg; (b) at least one second dose in the range of from 40-50 μg; and then (c) at least one third dose in the range of from 90-400 μg, wherein doses are administered every 6-8 days.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services, namely, providing information online or in person in the field of tumorous diseases and/or melanoma; organising events in the field of tumorous diseases and/or melanoma for educational purposes; conducting educational support services for patients, carers and healthcare professionals in the field of tumorous diseases and/or melanoma; conducting educational support programs for healthcare professionals in the field of tumorous diseases and/or melanoma. Medical services in the field of tumorous diseases and/or melanoma; healthcare services, namely, treatment of patients with tumorous diseases and/or melanoma; providing medical and healthcare information in the field of tumorous diseases and/or melanoma; individual medical counselling services provided to patients; medical information services provided via the internet; providing medical and healthcare information for healthcare professionals in the field of tumorous diseases and/or melanoma; providing medical advice in the field of tumorous diseases and/or melanoma; providing personalized healthcare and medical information in the nature of treatment plans and post prescription support in the field of tumorous diseases and/or melanoma.
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases and/or melanoma; pharmaceutical preparations, biological preparations and bispecific reagents for use in immunotherapy. Educational services, namely, providing information online or in person in the field of tumorous diseases and/or melanoma; organising events in the field of tumorous diseases and/or melanoma for educational purposes; conducting educational support services for patients, carers and healthcare professionals in the field of tumorous diseases and/or melanoma; conducting educational support programs for healthcare professionals in the field of tumorous diseases and/or melanoma. Medical services in the field of tumorous diseases and/or melanoma; healthcare services, namely, treatment of patients with tumorous diseases and/or melanoma; providing medical and healthcare information in the field of tumorous diseases and/or melanoma; individual medical counselling services provided to patients; medical information services provided via the internet; providing medical and healthcare information for healthcare professionals in the field of tumorous diseases and/or melanoma; providing medical advice in the field of tumorous diseases and/or melanoma; providing personalized healthcare and medical information in the nature of treatment plans and post prescription support in the field of tumorous diseases and/or melanoma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of tumorous diseases; pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of cancer; pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, urothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, hodgkin's lymphoma, and head and neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of tumorous diseases; pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of cancer; pharmaceutical preparations and biological preparations containing bispecific T-cell receptors for medical use, namely, for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, urothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, hodgkin's lymphoma, and head and neck cancers.
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
49.
BINDING MOLECULES AGAINST A PIWIL1 PEPTIDE-HLA COMPLEX
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
50.
BINDING MOLECULES AGAINST A PRAME PEPTIDE-HLA COMPLEX
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical testing; scientific research in the nature of conducting clinical trials for others; provision of information and consultancy in relation to the aforesaid services; scientific and technological services, namely, research and design of pharmaceutical compounds in the field of drug development for the treatment of cancer, infectious diseases and autoimmune diseases; pharmaceutical research and development services; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services
The present disclosure provides T cell receptor (TCR) fusion proteins comprising a TCR that binds to a GVYDGREHTV (SEQ ID NO:34) HLA-A*02 complex that is covalently linked to a T cell engaging domain that binds a protein expressed on a cell surface of a T cell and an antibody Fc domain, as well as polynucleotides, vectors, kits, host cells, pharmaceutical compositions, methods, and uses related thereto.
The present disclosure provides T cell receptor (TCR) fusion proteins comprising a TCR that binds to a GVYDGREHTV (SEQ ID NO:34) HLA-A*02 complex that is covalently linked to a T cell engaging domain that binds a protein expressed on a cell surface of a T cell and an antibody Fc domain, as well as polynucleotides, vectors, kits, host cells, pharmaceutical compositions, methods, and uses related thereto.
The present disclosure relates to the treatment of a cancer in a human subject where the treatment includes continuing administration of a T cell receptor (TCR) therapy in subjects whose ctDNA levels do not exceed baseline following administration of a first plurality of doses of TCR therapy. In particular, the present disclosure relates to treatment of a gp100 positive cancer in a human subject where the treatment includes administering tebentafusp to a subject who has or is suspected of having a gp100 positive cancer or treatment of a FRAME positive cancer in a human subject where the treatment includes administering a PRAME-targeting soluble bispecific TCR therapeutic (IMC-F106C) to a subject who has or suspected of having a FRAME positive cancer. The treatment includes continuing administration of tebentafusp or IMC-F106C in subjects whose ctDNA levels do not exceed baseline following administration of a first plurality of doses of tebentafusp or IMC-F106C.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
56.
COMPOSITIONS AND METHODS FOR TREATING CANCER THAT DEMONSTRATES DECREASING LEVELS OF CTDNA IN A SUBJECT
The present disclosure relates to the treatment of a cancer in a human subject where the treatment includes continuing administration of a T cell receptor (TCR) therapy in subjects whose ctDNA levels do not exceed baseline following administration of a first plurality of doses of TCR therapy. In particular, the present disclosure relates to treatment of a gplOO positive cancer in a human subject where the treatment includes administering tebentafusp to a subject who has or is suspected of having a gplOO positive cancer or treatment of a FRAME positive cancer in a human subject where the treatment includes administering a PRAME-targeting soluble bispecific TCR therapeutic (IMC-F106C) to a subject who has or suspected of having a FRAME positive cancer. The treatment includes continuing administration of tebentafusp or IMC-F106C in subjects whose ctDNA levels do not exceed baseline following administration of a first plurality of doses of tebentafusp or IMC-F106C.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, and head and neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, and head and neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to multi-domain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2), wherein VC1 and VC2 dimerise to form the pMHC binding domain; ii) an immune cell engaging domain comprising an antibody light chain variable domain (TCE-VL) linked to an antibody heavy chain variable domain (TCE-VH); and iii) a half-life extending domain comprising a first portion of an IgG Fc region (FC1) and a second portion of an IgG1 Fc region (FC2); wherein the multi-domain binding molecule comprises:a first polypeptide chain in which the immune cell engaging domain is linked to the N terminus of VC1; a second polypeptide chain in which VC2 is linked via its C terminus to the N terminus of FC1; and a third polypeptide chain comprising FC2; and wherein the pMHC binding domain and the immune cell engaging domain are capable of binding to a pMHC complex and a T cell respectively. The binding molecules can be used to treat diseases such as cancer, autoimmune diseases and infectious diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to multi-domain, single-chain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain which binds to a SLLQHLIGL (SEQ ID NO: 1) HLA-A*02 complex, the pMHC domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2); ii) a T cell engaging immune effector domain comprising an antibody light chain variable region (TCE-VL) and an antibody heavy chain variable region (TCE-VH); and iii) a half-life extending domain comprising a first IgG Fc region (FC1) and a second IgG Fc region (FC2), wherein the FC1 region and FC2 region dimerise to form an Fc domain. The binding molecules can be used to treat diseases such as cancer.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
67.
T CELL RECEPTOR FUSION PROTEINS SPECIFIC FOR MAGE A4
The present disclosure provides T cell receptor (TCR) fusion proteins comprising a TCR that binds to a GVYDGREHTV (SEQ ID NO:34) HLA-A*02 complex that is covalently linked to a T cell engaging domain that binds a protein expressed on a cell surface of a T cell and an antibody Fc domain, as well as polynucleotides, vectors, kits, host cells, pharmaceutical compositions, methods, and uses related thereto.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The present invention relates to multi-domain, single-chain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2); ii) a T cell engaging immune effector domain comprising an antibody light chain variable region (TCE-VL) and an antibody heavy chain variable region (TCE-VH); and iii) a half-life extending domain comprising a first IgG Fc region (FC1) and a second IgG Fc region (FC2), wherein the FC1 region and FC2 region dimerise to form an Fc domain. The binding molecules can be used to treat diseases such as cancer and infectious diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
70.
DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN
The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA (SEQ ID NO:1)-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, and head and neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use; immunotherapeutic drugs; reagents for medical use; diagnostic preparations; diagnostic reagents for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, and head and neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune diseases; biological preparations for the treatment of autoimmune diseases; immunotherapeutic drugs; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
77.
METHODS OF TREATING MELANOMA USING TEBENTAFUSP AND IMMUNE CHECKPOINT INHIBITORS
The present invention relates to the treatment of melanoma in a patient, where the method includes administering to a patient who has or is suspected of having melanoma a therapeutically effective amount of tebentafusp; and a therapeutically effective amount of an immune checkpoint inhibitor. In particular, patients may have metastatic melanoma that is refractory to treatment with an anti-PD(L)1 inhibitor in the metastatic setting or where the patient's melanoma is relapsed following treatment with an anti-PD(L)1 inhibitor.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
78.
METHODS OF TREATING MELANOMA USING TEBENTAFUSP AND IMMUNE CHECKPOINT INHIBITORS
The present invention relates to the treatment of melanoma in a patient, where the method includes administering to a patient who has or is suspected of having melanoma a therapeutically effective amount of tebentafusp; and a therapeutically effective amount of an immune checkpoint inhibitor. In particular, patients may have metastatic melanoma that is refractory to treatment with an anti-PD(L)1 inhibitor in the metastatic setting or where the patient's melanoma is relapsed following treatment with an anti-PD(L)1 inhibitor.
The present invention relates to specific binding molecules which bind to an HLA-restricted peptide derived from mutant KRAS. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to novel peptides derived from various target proteins, complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 15/62 - DNA sequences coding for fusion proteins
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules ofthe invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment ofHIV infected individuals.
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a PRAME positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 5-40µg; (b) at least one second dose in the range of from 15-80µg; and then (c) at least one third dose in the range of from 60-400µg, wherein the second dose is higher than the first dose and the third dose is higher than the second dose, and wherein doses are administered every 6-8 days.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a MAGE-A4 positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 10-20µg; (b) at least one second dose in the range of from 40-50µg; and then (c) at least one third dose in the range of from 90-400µg, wherein doses are administered every 6-8 days.
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a PRAME positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 5-40µg; (b) at least one second dose in the range of from 15-80µg; and then (c) at least one third dose in the range of from 60-400µg, wherein the second dose is higher than the first dose and the third dose is higher than the second dose, and wherein doses are administered every 6-8 days.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
The present invention provides a stabilised peptide-MHC (pMHC) complex, such as a peptide-HLA-E complex. The complex has a non-native linkage, such as a disulphide bond, between the C terminal anchor residue of the peptide, and an amino acid residue in the F pocket of the MHC binding groove.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of tumorous diseases;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of cancer;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of melanoma, lung
cancer, ovarian cancer, uterine cancer, breast cancer,
urothelial cancer, endometrial cancer, oesophageal cancer,
sarcoma, haematological cancers, acute myeloid leukemia,
chronic myeloid leukemia, Hodgkin's lymphoma, and head and
neck cancers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of tumorous diseases;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of cancer;
pharmaceutical preparations, biological preparations and
bispecific reagents for the treatment of melanoma, lung
cancer, ovarian cancer, uterine cancer, breast cancer,
urothelial cancer, endometrial cancer, oesophageal cancer,
sarcoma, haematological cancers, acute myeloid leukemia,
chronic myeloid leukemia, Hodgkin's lymphoma, and head and
neck cancers.
The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer; Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers.
100.
Binding molecules specific for HBV envelope protein
The present invention relates to specific binding molecules that bind the HLA-A*02 restricted peptide GLSPTVWLSV (SEQ ID NO: 1) derived from HBV envelope protein. The specific binding molecules may comprise alpha and/or beta TCR variable domains and may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious or malignant disease.
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
